Scientific Organizers: Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia Eric Vivier, Centre d’Immunologie de Marseille-Luminy / Innate Pharma, FranceCaroline Robert, Institute Gustave Roussy, FranceLewis L. Lanier, University of California, San Francisco, USA

Immunotherapy has revolutionized the treatment of many cancer types over the past five years. T cell checkpoint inhibitors have led the way and are the focus of most immunotherapy trials. However, innate and non-classical T cells contribute extensively to the tumor infiltrate and significantly affect the tumor immune response both in the tumor microenvironment and in circulation. This symposium aims to bring together academic and industry opinion leaders in the fields of innate immune cells, natural killer cells, tumor microenvironment, tumor immune suppression, novel immunotherapeutic strategies and clinical cancer immunotherapy to define the next wave of immunotherapy breakthroughs that reach beyond the current T cell checkpoints. The conference offers a unique opportunity for an audience of diverse immunology and cancer research backgrounds to come together and share cutting-edge insight into cancer immunology and rational approaches for therapeutic intervention that could be used as stand-alone or in combination with T cell checkpoint therapies. A key aim is to bring together experts with complementary interest in cancer immunotherapy who would not normally be drawn to common symposia and thereby foster new, dynamic collaborations to advance our understanding of tumor immunity.

Session Topics: • Clinical and Industry Advances in Cancer Immunotherapy • Workshop 1: Recent Advances in Drugging the Innate Immune Response• Myeloid Cells • ADCC and Phagocytosis • Tumor Microenvironment • Innate Checkpoints • Immune Evasion and Metastasis • NK Cells and ILCs • Workshop 2• Emerging Techniques in Immunotherapy

a 501(c)(3) nonprofit educational organization

Keystone Symposia in Keystone

Innate and Non-Classical Immune Cells in Cancer Immunotherapy Keystone Conference Center | Keystone, Colorado, USA | March 24–28, 2019

Scholarship/Discounted Abstract Deadline: Nov 27, 2018; Abstract Deadline: Dec 13, 2018; Discounted Registration Deadline: Jan 23, 2019

Visit www.keystonesymposia.org/19C5 for more details.

SUNDAY, MARCH 24Arrival and Registration

MONDAY, MARCH 25Welcome and Keynote Address *Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI,AustraliaRonald Levy, Stanford University, USAIn situ Therapeutic Vaccination with TLR Agonists

Clinical and Industry Advances in Cancer Immunotherapy *Caroline Robert, Institute Gustave Roussy, FranceAdvances in Melanoma ImmunotherapyRobert J. Johnston, Bristol-Myers Squibb, USAVISTA Is a pH-Selective PSGL-1 LigandStephan Vagner, Institut Curie, FranceTranslational Control of Immune Checkpoint and Consequences forCancer ImmunotherapyMichael Donio, Arch Oncology, USAShort Talk: Innate Checkpoint Inhibitor, AO-176, A Next GenerationCD47 Antibody with Novel Anti-Cancer PropertiesMichael Wichroski, Bristol-Myers Squibb, USAShort Talk: Preclinical Characterization of BMS-986299, aFirst-In-Class NLRP3 Innate Agonist with Potent Antitumor Activity,Alone and in Combination with Checkpoint Blockade

Workshop 1: Recent Advances in Drugging the Innate ImmuneResponse *Robert J. Johnston, Bristol-Myers Squibb, USAAmit Kumar, Johns Hopkins University, USAProtein Engineering of s-DAB389-IL2 for Cancer Immunotherapy andReduced Vascular Leak SyndromeElizabeth Sturgill, Providence Cancer Institute, USAGalectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-TargetingImmunotherapy, Leading to Reduced Immune Suppression andImproved Overall SurvivalMonia Draghi, Compass Therapeutics, USAPreclinical Characterization of NKp30xBCMA, a Novel Class ofNK-Cell Engagers Brian J. Francica, Tempest Therapeutics, USAMagnitude of Therapeutic STING Activation Critically Impacts CD8+ TCell-Mediated Anti-Tumor ImmunityCarina Hage, Roche Diagnostics GmbH, GermanySorafenib Initiates Macrophage-Natural Killer Cell Crosstalk byMacrophage PyroptosisManuela Zonca, PsiOxus Therapeutics, UKNG-641: A Tumor Stroma Targeting Transgene-Bearing OncolyticVirus

Myeloid Cells *Stefani Spranger, Massachusetts Institute of Technology, USACross-Presenting Dendritic Cells within the Tumor Microenvironment

Dmitry I. Gabrilovich, AstraZeneca, USAMyeloid-Derived Suppressor Cells in Cancer: Targeting OpportunitiesWeiping Zou, University of Michigan, USAMyeloid Cells in Cancer Immunity and Cancer StemnessMatthias Ernst, Olivia Newton-John Cancer Research Institute,AustraliaShort Talk: Targeting the Myeloid-Cell Specific Kinase HCK ImprovesAnti-Tumor ImmunityKatherine Brempelis, Seattle Children's Research Institute, USAShort Talk: Programming Macrophages to Alter the Solid TumorMicroenvironment Anje Cauwels, VIB and Ghent University, BelgiumShort Talk: Specific Targeting of Type I Interferon to the TumorMicroenvironment or to Dendritic Cells as a Novel, Generic, SafeCancer Immunotherapy

Poster Session 1

TUESDAY, MARCH 26ADCC and Phagocytosis *Irving L. Weissman, Stanford University, USACD47 in Tumor Immunity Sergio A. Quezada, University College London, UKImpact of Fc/FcR Interaction on the Activity of Immune ModulatoryAntibodiesMark S. Cragg, University of Southampton, UKTumour:Myeloid Interactions Mediating Antibody ImmunotherapyAndré Veillette, Institut de Recherches Cliniques de Montreal, CanadaNovel Roles of SLAM Family Receptors in Innate and Innate-LikeImmune CellsNicholas Wilson, Gilead Biosciences, Inc., USAShort Talk: Selective FcγR Co-Engagement on APCs Modulates theActivity of Therapeutic Antibodies Targeting T Cell AntigensDarienne R. Myers, Revolution Medicines, USAShort Talk: Shp1 Loss Drives Robust Anti-Tumor Immunity andEnhances Macrophage Effector Function

Tumor Microenvironment Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, USANK Cell-Mediated Cytotoxicity Contributes to Tumor Control by aCytostatic Drug Combination*Ursula Grohmann, University of Perugia, ItalyAn Intracellular Spatial Dynamics Dictates the Catalytic VersusSignaling Function of IDO1 in Dendritic CellsEric D. Frontera, Michigan State University, USAShort Talk: IgA Fc-Folate Conjugate Activates and RecruitsNeutrophils to Directly Target Triple-Negative Breast Cancer CellsChelsea Lassiter, University of Minnesota, USAShort Talk: Targeting STAT3 in Breast Cancer ModelsYing Jiang, University of Virginia, USAShort Talk: Multicellular Immunological Microenvironment DrivesTumor Initiation and Progression in Medulloblastoma

* Session Chair † Invited but not yet accepted Program current as of October 30, 2021. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.

KEYSTONE SYMPOSIAon Molecular and Cellular Biology

Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)March 24-28, 2019 • Keystone Resort • Keystone, CO, USA

Scientific Organizers: Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. LanierSponsored by BioLegend, Inc.

Discounted Abstract & Scholarship Deadline: December 4, 2018 / Abstract Deadline: December 13, 2018 / Discounted Registration Deadline: January 23, 2019

Poster Session 2

WEDNESDAY, MARCH 27Innate Checkpoints Carla V. Rothlin, Yale University, USAInnate Immune Checkpoints in CancerNicholas D. Huntington, Walter and Eliza Hall Institute, WEHI,AustraliaNatural Killer Cell Response to CancerAlberto Mantovani, Humanitas University, ItalyNew Vistas on Tumor-Associated Macrophages and Interaction withNK cells*Lewis L. Lanier, University of California, San Francisco, USANK Cell Memory to CancerDan Fu Ruan, Icahn School of Medicine at Mount Sinai, USAShort Talk: HLA-E Expression as a Major Determinant of AntitumorFunctionAngela L. Tata, Brown University, USAShort Talk: KLRG1 as a Novel Target for Immune Checkpoint Blockade

Immune Evasion and Metastasis *Caroline Robert, Institute Gustave Roussy, FranceKai W. Wucherpfennig, Dana-Farber Cancer Institute, USATargeting Immune Evasion from the MICA-NKG2D PathwayIlaria Malanchi, Francis Crick Institute, UKNeutrophils in the Metastatic Niche Sohail F. Tavazoie, Rockefeller University, USAMetastatic Progression as a Model for Understanding Anti-TumorImmunitySumera I. Ilyas, Mayo Clinic, USAShort Talk: PD-L1+ Protumor Macrophages Facilitate TumorProgression in Murine CholangiocarcinomaDebolina Ganguly, University of Texas Southwestern MedicalCenter, USAShort Talk: Pleiotrophin and Midkine Promote Metastasis inPre-Clinical Models of Breast CancerHin Ching Lo, Baylor College of Medicine, USAShort Talk: Circulating Tumor Cell Clusters Exhibit Enhanced ImmuneEvasion from Natural Killer Cells

Poster Session 3

THURSDAY, MARCH 28NK Cells and ILCs *Eric Vivier, Aix Marseille University and Inna Pharma, FranceTargeting NK Cells in CancerXiaokui Zhang, Celularity Inc., USAAdoptive NK Cell Therapies David H. Raulet, University of California, Berkeley, USAActivation and Inhibition of NK Cells in the Tumor Microenvironment,and Applications to Therapy Adelheid Cerwenka, University of Heidelberg, GermanyUnleashing Potent NK Cell Anti-Tumor Activity in Solid Tumors

Karl-Johan Malmberg, University of Oslo, NorwayShort Talk: Subset Plasticity and Functional Reprogramming duringNatural Killer Cell HomeostasisRobin S. Lindsay, University of Virginia, USAShort Talk: NK Cells Increase T Cell Infiltration and AntigenPresenting Cell Maturation within Melanoma Tumors

Workshop 2: Cellular Therapies & Biomarkers *Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI,AustraliaChao Guo, Nkarta Therapeutics, USAShort Talk: NK Cells Engineered to Express a BispecificCD123/NKG2D Chimeric Antigen Receptor (CAR) and IL-15 AsOff-the-Shelf Therapy for Acute Myeloid LeukemiaXiao-Hua Li, University of California, San Diego, USAShort Talk: Switchable Chimeric Antigen Receptor-EngineerediPSC-Derived Natural Killer Cells Michael Klichinsky, Carisma Therapeutics, USAHuman Chimeric Antigen Receptor (CAR) Macrophages for CancerImmunotherapyHuang Zhu, University of California, San Diego, USADeletion of CISH in Human Stem Cell Derived Natural Killer CellsPromotes in vivo Persistence and Enhances Anti-Tumor ActivityYago Pico de Coaña, Karolinska Institutet, SwedenMonitoring Advanced Melanoma Patients after Checkpoint Blockade:NK Cells and MDSCs as Predictive BiomarkersRichard P. Tobin, University of Colorado Anschutz Medical Campus,USAMucosal-Associated Invariant T Cells as a Novel Marker of Responseto Anti-PD1 Therapy in Melanoma Patients

Emerging Techniques in Immunotherapy Darrell J. Irvine, Massachusetts Institute of Technology, USACombination Immunotherapies Acting through Innate Immunity*Thomas Gebhardt, Doherty Institute for Infection and Immunity,AustraliaImaging Melanoma Immune Homeostasis in the Skin Bjorn Onfelt, KTH - Royal Institute of Technology, SwedenShort Talk: Microchip Platform for Imaging-Based Efficacy Testing ofCells and Reagents for ImmunotherapyDavide Bernareggi, University of California, San Diego, USAShort Talk: Use of CRISPR/Cas9 Screening System to Identify Genesthat Regulate NK Cell-Mediated Killing of Glioblastoma andMeningioma Adam Jelinski, Weizmann Institute, IsraelShort Talk: Single-Cell Analysis Illustrates Discrete Cellular DynamicsGenerated Between A Pure Checkpoint Blocking Antibody, aCTLA4mIgG1, and a Dual-Activity aCTLA4 mIgGa2 with Additional FcgREngaging Activity

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MARCH 29Departure

* Session Chair † Invited but not yet accepted Program current as of October 30, 2021. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.

KEYSTONE SYMPOSIAon Molecular and Cellular Biology

Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)March 24-28, 2019 • Keystone Resort • Keystone, CO, USA

Scientific Organizers: Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. LanierSponsored by BioLegend, Inc.

Discounted Abstract & Scholarship Deadline: December 4, 2018 / Abstract Deadline: December 13, 2018 / Discounted Registration Deadline: January 23, 2019